Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. Pathogenic mechanisms involved in psoriasiform skin lesions during.

Slides:



Advertisements
Similar presentations
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Advertisements

Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors
Immune mediators of tissue remodelling and lung function impairment in tuberculosis. Immune mediators of tissue remodelling and lung function impairment.
Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.
The beauty of TLR agonists for CTCL
What are the effector pathways, transcriptional regulators and activators of synovial tissue macrophages in healthy donors and in patients with RA in remission?
Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.
Figure 2 Cell-mediated disease mechanisms of lupus nephritis
Effective Management of Psoriatic Arthritis: Tailoring Treatments
Ex vivo effects of proNGF and NGF on JIA mononuclear cells.
A proposed model of cross-talk among Helicobacter pylori, dendritic cells (DC), gastric epithelial cells and myeloid-derived suppressor cells (MDSC) leading.
The role of viruses in acute exacerbations of asthma
IL-36γ Is Involved in Psoriasis and Allergic Contact Dermatitis
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
The Th17 immune response in renal inflammation
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production
INTERLEUKIN 10 (IL-10) CATEGORY: RECEPTORS & MOLECULES
Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.
Increased Sensitivity to Interferon-α in Psoriatic T Cells
The Multitasking Organ: Recent Insights into Skin Immune Function
The Multitasking Organ: Recent Insights into Skin Immune Function
Nat. Rev. Nephrol. doi: /nrneph
John T. Chang, William J. Sandborn  Gastroenterology 
F.L. van de Veerdonk, B.-J. Kullberg, M.G. Netea 
Cells and mediators of the immune-inflammatory ‘cascade’ leading to overt clinical rheumatoid arthritis are described. Cells and mediators of the immune-inflammatory.
IFN-β, IL-6, TNF-α and CCL2 release were determined by ELISA in culture supernatants of PBMC stimulated with LPS from Salmonella abortusequi (1 µg/mL Sigma–Aldrich.
Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.
ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.
Frequency of patients in flare at each time point over 3 months
The landscape of cytokine-producing CD4 T cell populations in the peripheral blood (PB) and in the joints. Venn diagrams show the frequency of overlapping.
Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle
Chemokine Receptors in T-Cell-Mediated Diseases of the Skin
A speculative scheme representing physiopathological mechanisms and clinical manifestations of psoriatic disease. A speculative scheme representing physiopathological.
ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the proportion of patients receiving CZP from.
Inflammatory cytokine secretion from THP-1 cells, luciferase reporter assay of Nod2-mediated NF-κB activation and NLRP3 expression. Inflammatory cytokine.
Pathogenesisof PsA and RA
Immune reconstitution inflammatory syndrome (IRIS) associated with Mycobacterium tuberculosis (TB) infection. a) In healthy individuals in response to.
IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1  Jurjen Tel, Ruurd Torensma, Carl G. Figdor, I.
The identification of leucocyte subset-specific type 1 interferon (IFN-1) modules. The identification of leucocyte subset-specific type 1 interferon (IFN-1)
Nat. Rev. Rheumatol. doi: /nrrheum
Mechanisms of chronic tophaceous gout.
Box plot showing median cytokine levels and IQRs for (A) IP-10, (B) TNF-α, (C) LT-α and (D) IFN-γ in controls and pSS fatigue groups. Box plot showing.
Treatments considered ‘Appropriate’ in at least one of the four subphenotypes of knee osteoarthritis.12 Quality of evidence is indicated by: bold=good;
Monitoring the induction of pro-inflammatory mediators and toll-like receptors (TLRs) following inhalation of AZD8848. Monitoring the induction of pro-inflammatory.
IFN and neutrophil gene expression studies.
Frank O. Nestle, Curdin Conrad  Journal of Investigative Dermatology 
Effect of CIA and treatment with 3,4-dichloropropionaniline (DCPA) on production of key serum inflammatory factors. Effect of CIA and treatment with 3,4-dichloropropionaniline.
Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.
Prescription rates of (A) NSAIDs, glucocorticoids and analgaesics, (B) TNF inhibitors and synthetic DMARDs and (C) combination therapy of NSAIDs with TNF.
Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. (A)
Mechanisms of virus-induced airway inflammation in chronic obstructive pulmonary disease (COPD). Mechanisms of virus-induced airway inflammation in chronic.
Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria. Inhibiting or altering.
Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.
IFNα Induces MDSC Maturation and Loss of Suppressive Function
Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.
Cytokine synthesis from mononuclear cells.
Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.
Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,
Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;
Follow-up and cause of anti-TNF-α discontinuation in 15 patients with rhupus. anti-TNF-α, antitumour necrosis factor alpha; ESR, erythrocyte sediment rate;
Fig. 2. Effect of activated vitamin D on immune cells
Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.
The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α,
proNGF and NGF activated different intracellular pathways.
Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.
Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. Biologic DMARDs and targeted synthetic DMARDs approved.
Presentation transcript:

Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. Pathogenic mechanisms involved in psoriasiform skin lesions during anti-TNF-α therapy. TNF-α, IL-17 and IFN-α are the main cytokines that contribute to the development of psoriatic lesions. TNF-α inhibits the activity of plasmacytoid dendritic cells (pDC), which are key producers of IFN-α. During anti-TNF-α treatment, there is an unopposed IFN-α production by pDC. In parallel, IFN-α leads to the expression of chemokines such as CXCR3 on T cells, favouring T cell homing to the skin. IFN-α also stimulates and activates T cells to produce TNF-α and IL-17, sustaining inflammatory mechanisms for psoriasis lesions. IFN-α, interferon α; IL-17, interleukin 17; TNF-α, tumour necrosis factor α. Éric Toussirot, and François Aubin RMD Open 2016;2:e000239 Copyright © BMJ Publishing Group & EULAR. All rights reserved.